Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases

Pharmacogenomics

Volumn 12, Issue 10, 2011, Pages 1449-1463

  Stamp, Lisa K ^b   Roberts, Rebecca L ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

folate; methotrexate; pharmacogenetics; rheumatoid arthritis; SNP

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADENINE; ADENOSINE; CYTOKINE; CYTOSINE; DIHYDROFOLATE REDUCTASE; DIHYDROFOLIC ACID; FOLIC ACID; FOLINIC ACID; METHOTREXATE; PLACEBO; POLYGLUTAMIC ACID; REDUCED FOLATE CARRIER; REDUCED FOLATE CARRIER 1 PROTEIN; THYMIDYLATE SYNTHASE; THYMINE; UNCLASSIFIED DRUG;

ALOPECIA; ANTIINFLAMMATORY ACTIVITY; BLOOD TOXICITY; BONE MARROW TOXICITY; CELL LEVEL; DISEASE CONTROL; DRUG ANTAGONISM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TRANSPORT; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; GENE; GENETIC POLYMORPHISM; GENETIC SCREENING; GENOME ANALYSIS; HUMAN; INTRACELLULAR TRANSPORT; JUVENILE RHEUMATOID ARTHRITIS; LIVER TOXICITY; LOW DRUG DOSE; LUNG TOXICITY; MTHFR GENE; MUCOSA INFLAMMATION; PHARMACOGENETICS; PREDICTION; PROSPECTIVE STUDY; PSORIATIC ARTHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN TOXICITY; STANDARDIZATION; TREATMENT RESPONSE; VASCULITIS;

ANTIRHEUMATIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLIC ACID; GENOME-WIDE ASSOCIATION STUDY; HUMANS; METABOLIC NETWORKS AND PATHWAYS; METHOTREXATE; POLYGLUTAMIC ACID; POLYMORPHISM, GENETIC; REDUCED FOLATE CARRIER PROTEIN; RHEUMATIC DISEASES;

EID: 80054937075     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.86     Document Type: Review

References (94)

1. Ranganathan P, Culverhouse R, Marsh S et al. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J. Rheumatol. 35(4), 572-579 (2008). (Pubitemid 351500051)
2. Tishler M, Caspi D, Graff E et al. Synovial and serum levels of methotrexate during methotrexate therapy of rheumatoid arthritis. Br. J. Rheumatol. 28(5), 422-423 (1989). (Pubitemid 19248531)
3. Jolivet J, Faucher F, Pinard MF. Influence of intracellular folates on methotrexate metabolism and cytotoxicity. Biochem. Pharmacol. 36(19), 3310-3312 (1987). (Pubitemid 17161023)
4. Kennedy DG, van den Berg HW, Clarke R, Murphy RF. The effect of leucovorin on the synthesis of methotrexate poly-g-glutamates in the MCF-7 human breast cancer cell line. Biochem. Pharmacol. 34(16), 2897-2903 (1985). (Pubitemid 15244848)
5. Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub R. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann. Rheum. Dis. 60(8), 729-735 (2001). (Pubitemid 32685871)
6. Plant M, Jones P, Saklatvala J, Ollier W, Dawes P. Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study. J. Rheumatol. 25(3), 417-426 (1998). (Pubitemid 28109339)
7. van der Heijde D. Joint erosions and patients with early rheumatoid arthritis. Br. J. Rheumatol. 34(Suppl. 2), 74-78 (1995).
8. Wolfe F, Sharp J. Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis Rheum. 41(9), 1571-1582 (1998). (Pubitemid 28459915)
9. Graudal N, Tarp U, Jurik A et al. Inflammatory patterns in rheumatoid arthritis estimated by the number of swollen and tender joints, the erythrocyte sedimentation rate and hemoglobin. Long-term course and association to radiographic progression. J. Rheumatol. 27(1), 47-57 (2000). (Pubitemid 30058628)
10. Dalrymple JM, Stamp LK, O'Donnell JL et al. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 58(11), 3299-3308 (2008).
11. Visser K, Katchamart W, Loza E et al. Multi-national evidence based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis. integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E initiative. Ann. Rheum. Dis. 68(7), 1086-1093 (2009).
12. Dervieux T, Furst D, Lein DO et al. Pharmacogenetic and metabolite measurements are associated with clinical status in rheumatoid arthritis patients treated with methotrexate. Results of a multicentered cross sectional observational study. Ann. Rheum. Dis. 64(8), 1180-1185 (2005). (Pubitemid 41113353)
13. Stamp LK, O'Donnell JL, Chapman PT et al. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients on longterm MTX therapy. Arthritis Rheum. 62(2), 359-368 (2010).
14. Becker M, Gaedigk R, Van Haandel L et al. The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. Arthritis Rheum. 63(1), 276-285 (2011).
15. Dolezalová P, Krijt J, Chládek J, Nemcová D, Hoza J. Adenosine and methotrexate polyglutamate concentrations in patients with juvenile arthritis. Rheumatology 44(1), 74-79 (2005). (Pubitemid 40124335)
16. Brooks AJ, Begg EJ, Zhang M, Frampton CM, Barclay ML. Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Ther. Drug Monit. 29(5), 619-625 (2007). (Pubitemid 47494061)
17. Angelis-Stoforidis P, Vajda FJE, Christophidis N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin. Exp. Rheumatol. 17(3), 313-320 (1999). (Pubitemid 29265678)
18. Dervieux T, Furst D, Lein DO et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 50(9), 2766-2774 (2004). (Pubitemid 39209513)
19. Ahern MJ, Kevat S, Hill W et al. Hepatic methotrexate content and progression of hepatic fibrosis. preliminary findings. Ann. Rheum. Dis. 50(7), 477-480 (1991).
20. Stamp LK, O'Donnell JL, Chapman PT et al. Determinants of red blood cell methotrexate polyglutamate concentrations in patients with rheumatoid arthritis on long-term MTX. Arthritis Rheum. 60(8), 2248-2256 (2009).
21. Becker M, van Haanhel L, Gaedigk R et al. Analysis of intracellular methotrexate polyglutamates in juvenile idiopathic arthritis. Effect of route of administration upon intracellular methotrexate polyglutamate variability. Arthritis Rheum. 62(6), 1803-1812 (2010).
22. Dervieux T, Zablocki R, Kremer J. Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. Rheumatology 49(12), 2337-2345 (2010).
23. Stamp L, Chapman P, O'Donnell J et al. Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. Pharmacogenet. Genomics 20(6), 367-276 (2010).
24. Ortiz Z, Moher D, Shea B et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst. Rev. 2, CD000951 (2000).
25. Ortiz Z, Shea B, Suarez-Almazor M et al. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A meta analysis of randomized controlled trials. J. Rheumatol. 25(1), 36-43 (1998). (Pubitemid 28060115)
26. van Ede A, Laan R, rood M et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum. 44(7), 1515-1524 (2001).
27. Morgan S, Baggott J, Alarcon G, Koopman W. Folic acid and folinic acid supplementation during low dose methotrexate therapy for rheumatoid arthritis: comment on article by van Ede et al. Arthritis Rheum. 46(5), 1413-1414 (2002). (Pubitemid 34525858)
28. Khanna D, Park G, Paulus H et al. Reduction in efficacy of methotrexate by the use of folic acid. Post hoc analysis from two randomised controlled studies. Arthritis Rheum. 52(10), 3030-3038 (2005). (Pubitemid 41447082)
29. Chladek J, Simkova M, Vaneckova J et al. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur. J. Clin. Pharmacol. 64(4), 347-355 (2008).
30. Dervieux T, Greenstein N, Kremer J. Pharmacogenomic and metabolic markers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum. 54(10), 3095-3103 (2006). (Pubitemid 44622078)
31. Aggarwal P, Naik S, Mishra K, Aggarwal A, Misra R. Correlation between methotrexate efficacy and toxicity with C677T polymorphism of the methylenetetrahydrofolate gene in rheumatoid arthritis patients on folate supplementation. Indian J. Med. Res. 124, 521-526 (2006). (Pubitemid 46157711)
32. Dervieux T, Kremer J, Lein DO et al. Contribution of common polymorphisms in reduced folate carrier and gamma-glutamyl hydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 14(11), 733-739 (2004). (Pubitemid 39552788)
33. Dervieux T, Wessels J, van der Straaten T et al. Gene-gene interactions in folate and adenosine biosyntheses pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. Pharmacogenet. Genomics 19(12), 935-944 (2009).
34. Hughes L, Beasley T, Patel H et al. Racial/ethnic differences in allele frequencies of single nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence in response to methotrexate in rheumatoid arthritis. Ann. Rheum. Dis. 65(9), 1213-1218 (2006). (Pubitemid 44277399)
35. Urano W, Taniguchi A, Yamanaka H et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 12(3), 183-190 (2002). (Pubitemid 34596782)
36. Weisman M, Furst D, Park G et al. Risk genotypes in folate-dependent enzymes and their association with methotrexate related side effects in rheumatoid arthritis. Arthritis Rheum. 54(2), 607-612 (2006). (Pubitemid 43228638)
37. Wessels J, de Vries-Bouwstra J, Heijmans B et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum. 54(4), 1087-1095 (2006). (Pubitemid 43672921)
38. Wessels JAM, van der Kooij SM, Cessie S et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 56(6), 1765-1775 (2007). (Pubitemid 47110376)
39. Chandran V, Siannis F, Rahman P, Pellett F, Gladman D. Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis. J. Rheumatol. 37(7), 1508-1512 (2010).
40. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease. A common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10(1), 111-113 (1995).
41. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol. Genet. Metab. 64(3), 169-172 (1998). (Pubitemid 28453294)
42. Fisher M, Cronstein B. Meta-analysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J. Rheumatol. 36(3), 539-545 (2009).
43. Lee YH, Song G. Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis. Clin. Drug Investig. 30(2), 101-108 (2010).
44. Ranganathan P, Culverhouse R, Marsh S et al. Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis. Pharmacogenomics 5(5), 559-569 (2004). (Pubitemid 39023072)
45. Inoue S, Hashiguchi M, Chiyoda T et al. Pharmacogenetic study of methylenetetrahydrofolate reductase and thymidylate synthase in Japanese and assessment of ethnic and gender differences. Pharmacogenomics 8(1), 41-47 (2007). (Pubitemid 46157756)
46. Hayashi H, Fujimaki C, Inoue K, Suzuki T, Itoh K. Genetic polymorphisms of C452T (T127I) in human g-glutamyl hydrolase in a Japanese population. Biol. Pharm. Bull. 30(4), 839-841 (2007). (Pubitemid 46571013)
47. Hayashi H, Horino M, Morishita M et al. Dihydrofolate reductase gene intronic 19-bp deletion polymorphism in a Japanese population. Drug Metab. Pharmacokinet. 25(5), 516-518 (2010).
48. de Rotte M, Luime J, Bulatovic M et al. Do snapshot statistics fool us in MTX pharmacogenetics studies in arthritis research? Rheumatology 49(6), 1200-1201 (2010).
49. van Gestel AM, Haagsma CJ, van Riel PLCM. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 41(10), 1845-1850 (1998). (Pubitemid 28465539)
50. Ghodke Y, Chopra A, Shintre P et al. Profiling single nucleotide polymorphisms (SNPs) across intracellular folate metabolic pathways in healthy Indians. Indian J. Med. Res. 133, 274-279 (2011).
51. Ulvik A, Ueland P, Fredriksen A et al. Functional inference of the methylenetetrahydrofolate reductase 677C T and 1298A C polymorphisms from a large-scale epidemiological study. Hum. Genet. 121(1), 57-64 (2007). (Pubitemid 46421141)
52. van Ede A, Laan R, Blom H et al. The C677T mutation in the methylenetetrahydrofolate reductase gene. A risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum. 44(11), 2525-2530 (2001). (Pubitemid 33049330)
53. van der Heijden J, Dijkmans B, Scheper R, Jansen G. Drug insight: resistance to methotrexate and other disease-modifying antirheumatic drugs-from bench to bedside. Nat. Clin. Pract. Rheumatol. 3(1), 26-34 (2007).
54. Hider S, Owen A, Hartkoorn R et al. Down regulation of multidrug resistance protein-1 expression in patients with early rheuatmoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug Ann. Rheum. Dis. 65, 1390-1393 (2006). (Pubitemid 44620452)
55. Agarwal V, Mittal S, Misra R. Expression of multidrug resistance-1 protein correlates with disease activity rather than the refractoriness to methotrexate therapy in rheumatoid arthritis. Clin. Rehumatol. 28, 427-433 (2009).
56. Schroder H, Fogh K. Methotrexate and its polyglutamates in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukaemia. Cancer Chemother. Pharmacol. 21(2), 145-149 (1988). (Pubitemid 18087030)
57. Tonetti C, Amiel J, Munnich A, Zittoun J. Impact of new mutations in the methylenetetrahydrofolate reductase gene assessed on biochemical phenotypes: a familial study. J. Inherit. Metab. Dis. 24(8), 833-842 (2001). (Pubitemid 34192857)
58. Marie S, Heron B, Bitoun P et al. AICA-ribosiduria. a novel, neurologically devastating inborn error of purine biosynthesis caused by mutation of ATIC. Am. J. Hum. Genet. 74(6), 1276-1281 (2004). (Pubitemid 38669327)
59. Toffoli G, De Mattia E. Pharmacogenetic relevance of MTHFR polymorphisms. Pharmacogenomics J. 9(9), 1195-1206 (2008).
60. Kurzawski M, Pawlik A, Kozak M, Banach J, Drozdzik M. 677C T and 1298A C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics J. 8(11), 1551-1559 (2007). (Pubitemid 350286399)
61. van der Straaten R, Wessels J, de Vries-Bouwstra J et al. Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients. Pharmacogenomics J. 8(2), 141-150 (2007).
62. Sharma S, Das M, Kumar A et al. Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis among Indians. Pharmacogenet. Genomics 18(12), 1041-1049 (2008).
63. Sato Y, Yamamoto N, Kunitoh H et al. Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel. J. Thorac. Oncol. 6(1), 132-138 (2011).
64. Wu C, Xu B, Yuan P et al. Genome-wide examination of genetic variants associated with response to platinum-based chemotherapy in patients with small-cell lung cancer. Pharmacogenet. Genomics 20(6), 389-395 (2010).
65. Dubinsky M, Mei L, Friedman M et al. Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease. Inflamm. Bowel Dis. 16(8), 1357-1366 (2010).
66. Comabella M, Craig D, Morcillo-Suárez C et al. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch. Neurol. 66(8), 972-978 (2009).
67. Prashker M, Meenan R. The total costs of drug therapy for rheumatoid arthritis. A model based on costs of drug, monitoring and toxicity. Arthritis Rheum. 38(3), 318-325 (1995).
68. Goldman I, Matherly L. The cellular pharmacology of methotrexate. Pharmacol. Ther. 28(1), 77-102 (1985). (Pubitemid 15015465)
69. Henderson GB, Tsuji J, Kumar H. Transport of folate compounds by leukemic cells. Evidence for a single influx carrier for methotrexate, 5-methyltetrahydrofolate, and folate in CCRF-CEM human lymphoblasts. Biochem. Pharmacol. 36(18), 3007-3014 (1987). (Pubitemid 17142308)
70. Chabner BA, Allegra C, Curt G et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J. Clin. Invest. 76(3), 907-912 (1985).
71. Galivan J, Ryan T, Chave K et al. Glutamyl hydrolase. Pharmacological role and enzymatic characterization. Pharmacol. Ther. 85(3), 207-215 (2000). (Pubitemid 30160790)
72. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 61(19), 7225-7232 (2001). (Pubitemid 32946519)
73. White J, Goldman I. Mechanism of action of methotrexate. IV. Free intracellular methotrexate required to suppress dihydrofolate reduction to tetrahydrofolate by Ehrlich ascites tumor cells in vitro. Mol. Pharmacol. 12(5), 711-719 (1976).
74. Allegra C, Chabner B, Drake J et al. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J. Biol. Chem. 260(17), 9720-9726 (1985). (Pubitemid 15013030)
75. Szeto D, Cheng Y, Rosowsky A et al. Human thymidylate synthetase-III. Effects of methotrexate and folate analogs. Biochem. Pharmacol. 28(17), 2633-2637 (1979). (Pubitemid 10229281)
76. Klein T, Chang J, Cho M et al. Integrating genotype and phenotype information. an overview of the PharmGKB project. Pharmacogenomics J. 1(3), 167-170 (2001). (Pubitemid 33756654)
77. Allegra CJ, Drake JC, Jolivet J, Chabner BA. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc. Natl Acad. Sci. USA 82(15), 4881-4885 (1985). (Pubitemid 15249910)
78. Baggott JE, Vaughn WH, Hudson BB. Inhibition of 5-aminoimidazole-4- carboxamide ribotide transformylase, adenosine deaminase and 5́-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem. J. 236(1), 193-200 (1986). (Pubitemid 16095531)
79. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J. Clin. Invest. 92(6), 2675-2682 (1993). (Pubitemid 24006532)
80. Pawlik A, Wrzesniewska J, Fiedorowicz-Fabrycy I, Gawronska-Szklarz B. The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int. J. Clin. Pharmacol. Ther. 42(9), 496-503 (2004). (Pubitemid 39255621)
81. Pawlik A, Baskiewicz-Masiuk M, Machalinski B, Kurzawski M, Gawronska-Szklarz B. Involvement of C3435T and G2677T multidrug resistance gene polymorphisms in release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone. Eur. J. Pharmacol. 528(1-3), 27-36 (2005).
82. Drozdzik M, Rudas T, Pawlik A et al. The effect of 3435C T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur. J. Clin. Pharmacol. 62(11), 933-937 (2006). (Pubitemid 44657627)
83. Takatori R, Takahashi K, Tokunaga D et al. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin. Exp. Rheumatol. 24(5), 546-554 (2006). (Pubitemid 44911249)
84. Bohanec Grabar P, Logar D, Lestan B, Dolzan V. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur. J. Clin. Pharmacol. 64(11), 1057-1068 (2008).
85. Campalani E, Arenas M, Marinaki AM et al. Polymorphisms in folate, pyrimidine and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J. Invest. Dermatol. 127(8), 1860-1867 (2007). (Pubitemid 47075365)
86. Kim SK, Jun JB, El-Sohemy A, Bae SC. Cost-effectiveness analysis of MTHFR polymorphism screening by polymerase chain reaction in Korean patients with rheumatoid arthritis receiving methotrexate. J. Rheumatol. 33(7), 1266-1274 (2006). (Pubitemid 44025139)
87. Hinks A, Moncrieffe H, Martin P et al. Assocation of the 5-aminoimidazole-4-carboxamide ribonucleotise transformylase gene with response to methotrexate in juvenile idiopathic arthritis. Ann. Rheum. Dis. 70(8), 1395-1400 (2011).
88. Haagsma CJ, Blom HJ, van Riel PLCM et al. Influence of sulphasalazine, methotrexate and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann. Rheum. Dis. 58(2), 79-84 (1999). (Pubitemid 29116306)
89. Tukova J, Chladek J, Hroch M et al. 677TT genotype is associated with elevated risk of methotrexate (MTX) toxicity in juvenile idiopathic arthritis. treatment outcome, erythrocyte concentrations of MTX and folates, and MTHFR polymorphisms. J. Rheumatol. 37(10), 2180-2186 (2010).
90. Schmeling A, Biber D, Heins S, Horneff G. Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis. J. Rheumatol. 32(9), 1832-1836 (2005). (Pubitemid 41324827)
91. James HM, Gillis D, Hissaria P et al. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. J. Rheumatol. 35(4), 562-571 (2008). (Pubitemid 351500050)
92. Berkun Y, Levartovsky D, Rubinow A et al. Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann. Rheum. Dis. 63(10), 1227-1231 (2004). (Pubitemid 39273498)
93. Drozdzik M, Rudas T, Pawlik A et al. Reduced folate carrier-1 80G A polymorphism affects methotrexate treatment outcomes in rheumatoid arthritis. Pharmacogenomics J. 7(6), 404-407 (2007). (Pubitemid 350192886)
94. Baslund B, Gregers J, Nielsen C. Reduced folate carrier polymorphism determines methotrexate uptake by B cells and CD4+ T cells. Rheumatology 47(4), 451-453 (2008).